A Phase 4 interventional study of ziprasidone hydrochloride and olanzapine in Acute Mania and Bipolar Disorder, Manic, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-03-29.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ziprasidone in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. ziprasidone · Bipolar Disorder.
Among the 28 studies testing ziprasidone in Bipolar Disorder, this one is the 17th largest by enrollment, is one of 9 that started in 2006, is one of 11 in phase 4, and was the 10th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 28 studies testing ziprasidone in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
ziprasidone: first FDA approval 2001 (GEODON). What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 9 started in 2006.
This study's enrollment of 29 is below the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 39 across the 28 interventional studies. Of the 25 that completed or were terminated, 22 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
18 studies in Bipolar Disorder by Viatris Inc.: none open now, none under way, none of them phase 3. Of 16 finished, 13 (81%) have results posted.
Among the 18 studies in Bipolar Disorder by Viatris Inc., this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2006, is the only one in phase 4, and was the 7th registered.
Viatris Inc.’s Bipolar Disorder studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ziprasidone in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 18 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and tolerability of ziprasidone versus olanzapine in the treatment of acute mania. An open label extension will further evaluate the efficacy, safety, and tolerability of ziprasidone compared with olanzapine. Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on July 30, 2007. Subjects that were enrolled at the time completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment. The Last Subject Last Visit was January 10, 2008.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ziprasidone hydrochloride
Drug: olanzapine
Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
Also known as: Geodon, Zeldox
Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
Mean Reduction in Young Mania Rating Scale (YMRS) Score During the Double Blind Phase.
YMRS is 11-item instrument with scales between 0 to 4 for 7 items and scales between 0 and 8 for 4 items. 0 is normal and either 4 or 8 is the highest level of abnormal, depending on the item.
Time frame: 4 weeks
Change From Baseline in Clinical Global Impressions Scale for Use in Bipolar Illness Scores; Montgomery Asberg Depression Scale Scores in the Double Blind Phase.
Time frame: up to 10 weeks
Change From Baseline in Global Assessment of Functioning Scale Scores, Treatment Satisfaction Questionnaire for Medication, Quality of Life Enjoyment and Satisfaction Questionnaire in the Double Blind Phase.
Time frame: 6 months
Percentage of Patients With Symptomatic Remission After 4, 6 and 10 Weeks of Treatment and at the End of the Double-blind Phase.
Time frame: 4, 6 and 10 weeks
Time to Symptomatic Remission in the Double Blind Phase.
Time frame: up to 10 weeks
Percentage of Patients With Clinical Response After 6 Weeks of Double-blind Treatment.
Time frame: 6 weeks
Percentage of Patients With Symptomatic Relapse of Mania and/or Symptomatic Relapse of Depression During the Open Label Phase.
Time frame: 6 months
47 centers in Europe.
| Milestone | Ziprasidone | Olanzapine |
|---|---|---|
| Started | 15 | 14 |
| Completed | 5 | 2 |
| Not completed | 10 | 12 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Lack of efficacy | 3 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Symptomatic deterioration | 1 | 1 |
| Withdrew: Subject no longer willing to participate | 2 | 2 |
| Withdrew: Study terminated by sponsor | 1 | 0 |
| Withdrew: Withdrew patient after sae resolved | 1 | 0 |
| Withdrew: Protocol violation | 0 | 2 |
YMRS is 11-item instrument with scales between 0 to 4 for 7 items and scales between 0 and 8 for 4 items. 0 is normal and either 4 or 8 is the highest level of abnormal, depending on the item.
No measurements were reported for this outcome.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ziprasidone | — | — | — |
| Olanzapine | — | — | — |
| Event | Ziprasidone | Olanzapine |
|---|---|---|
| Oculogyric crisisEye disorders | 1/15 | 0/14 |
| Disease progressionGeneral disorders | 1/15 | 0/14 |
| laryngospasmRespiratory, thoracic and mediastinal disorders | 1/15 | 0/14 |
| Event | Ziprasidone | Olanzapine |
|---|---|---|
| tremorNervous system disorders | 1/15 | 3/14 |
| somnolenceNervous system disorders | 3/15 | 1/14 |
| Dry mouthGastrointestinal disorders | 0/15 | 2/14 |
| fatigueGeneral disorders | 0/15 | 2/14 |
| increased appetiteMetabolism and nutrition disorders | 0/15 | 2/14 |
| insomniaPsychiatric disorders | 2/15 | 0/14 |
| AnemiaBlood and lymphatic system disorders | 0/15 | 1/14 |
| HyperprolactinaemiaEndocrine disorders | 0/15 | 1/14 |
| flatulenceGastrointestinal disorders | 0/15 | 1/14 |
| gingivitisGastrointestinal disorders | 0/15 | 1/14 |
| Age, Customized(participants) | Ziprasidone | Olanzapine | Total |
|---|---|---|---|
| 18-44 years | 9 | 7 | 16 |
| 45-64 years | 6 | 7 | 13 |
| Sex: Female, Male(Participants) | Ziprasidone | Olanzapine | Total |
|---|---|---|---|
| Female | 10 | 5 | 15 |
| Male | 5 | 9 | 14 |
The record gives a start of Nov 2006, a primary completion of Jul 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2009, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziprasidone
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →